Richard Dana Ono

This profile gathers the share dealings of Richard Dana Ono across 2 companies, led by Inhibitor Therapeutics, Inc. and Lipocine Inc. In total, 10 filings cover trades dated from 8 March 2017 to 20 March 2023.

The open-market side counts 1 purchase for €1,274 alongside 1 sale for €2,543. Netting one side against the other leaves €1,269 of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 3 share grants and 5 option exercises. So far in 2023, the count stands at 1 purchase and no sales.

Most recently, on 20 March 2023, the filings show an open-market purchase worth €1,274 in Lipocine Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.